Working… Menu

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02279394
Recruitment Status : Active, not recruiting
First Posted : October 31, 2014
Last Update Posted : April 23, 2021
Bristol-Myers Squibb
Blood Cancer Research Partnership
Multiple Myeloma Research Consortium
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Irene Ghobrial, MD, Dana-Farber Cancer Institute

Brief Summary:
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Condition or disease Intervention/treatment Phase
Smoldering Myeloma Smoldering Multiple Myeloma Drug: Elotuzumab Drug: Lenalidomide Drug: Dexamethasone Phase 2

Detailed Description:
This research study is a Phase II clinical trial, which tests the effectiveness of the investigational drugs elotuzumab, lenalidomide and dexamethasone in smoldering multiple myeloma. Recent research studies have shown that early treatment of smoldering multiple myeloma may delay or prevent the progression to active multiple myeloma. The purpose of this research study is to learn whether the combination of elotuzumab, lenalidomide and dexamethasone works in treating smoldering multiple myeloma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Actual Study Start Date : December 11, 2014
Estimated Primary Completion Date : May 1, 2021
Estimated Study Completion Date : October 2023

Intervention Details:
  • Drug: Elotuzumab
    10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
    Other Name: HuLuc63
  • Drug: Lenalidomide
    25 mg Oral; Days 1-21 days Cycles 1-24
    Other Name: REVLIMID
  • Drug: Dexamethasone
    40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
    Other Name: Decadron

Primary Outcome Measures :
  1. Proportion of patients who are progression free at 2 years [ Time Frame: 2 Years ]
    Time from protocol therapy initiation to progression to symptomatic myeloma

Secondary Outcome Measures :
  1. Response rate [ Time Frame: 2 Years ]
    Response rate based on the IMWG criteria

  2. Safety of the combination therapy [ Time Frame: 4 years ]
    safety of the combination of Elotuzumab, lenalidomide+/- dexamethasone

  3. Time to progression [ Time Frame: 4 years ]
    Time from initiation of therapy to progression defined by the IMWG criteria.

  4. Overall survival [ Time Frame: 2 Years ]
    Time from initiation of therapy to death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Must have smoldering myeloma with high risk markers based on the Mayo OR the Spanish criteria as described below
  • >10% plasma cells in the bone marrow and any one or more of the following:

    • Serum M protein of 3 g/dL or greater
    • IgA SMM
    • Immunoparesis with reduction of two uninvolved immunoglobulin isotypes
    • Serum involved/uninvolved free light chain ratio ≥8 (but less than 100)
    • Progressive increase in M protein level (Evolving type of SMM)†
    • Bone marrow clonal plasma cells 50-60%
    • Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are clonal) and reduction of one or more uninvolved immunoglobulin isotypes
    • t (4;14) or del 17p or 1q gain
    • Increased circulating plasma cells
    • MRI with diffuse abnormalities or 1 focal lesion
    • PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction † Increase in serum monoclonal protein by ≥25% on two successive evaluations within a 6 month period
  • No evidence of CRAB (see below for details) criteria or new criteria of active multiple myeloma which including the following:

    • Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper limit of normal or >.275 mmol/dL)
    • Renal insufficiency (attributable to myeloma)
    • Anemia (Hb 2g/dL below the lower limit of normal or <10g/dL)
    • Bone lesions (lytic lesions or generalized osteoporosis with compression fractures)
    • No evidence of the following new criteria for active MM including the following: Bone marrow plasma cells ≥ 60%, Serum involved/uninvolved FLC ratio ≥100, and MRI with more than one focal lesion

      • Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible
  • ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)
  • The following laboratory values obtained ≤ 14 days prior to registration:

    • ANC ≥1000/µL
    • PLT ≥ 50,000/µL
    • Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.)
    • AST ≤ 3 x institutional upper limit of normal (ULN)
    • ALT ≤ 3 x institutional upper limit of normal (ULN)
    • Estimated creatinine clearance ≥ 60mL/min or a creatinine ≤ 2.2 mg/dL
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
  • Females of childbearing potential* must have a negative serum or urine pregnancy test
  • Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy
  • Ability to understand and the willingness to sign a written informed consent.
  • Exclusion Criteria:
  • Symptomatic Multiple Myeloma or any evidence of CRAB criteria including the new criteria for overt myeloma. Any prior therapy for active Myeloma should also be excluded. Prior therapy for smoldering myeloma is not an exclusion criteria. Bisphosphonates are not excluded
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational. Prior therapy with bisphosphonate is allowed. Prior radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials for smoldering MM or MGUS are allowed as long as the last therapy was at least 2 months prior and there was no improvement in M spike
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study
  • Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
  • Uncontrolled intercurrent illness
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomide
  • Known seropositive for or active viral infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus. Patients who are seropositive because of hepatitis B virus vaccine are eligible

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02279394

Layout table for location information
United States, Colorado
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
United States, Connecticut
St Francis Hospital and Medical Center
Hartford, Connecticut, United States, 06105
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maine
Eastern Maine Medical Center
Brewer, Maine, United States, 04412
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, North Carolina
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Sponsors and Collaborators
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Blood Cancer Research Partnership
Multiple Myeloma Research Consortium
The Leukemia and Lymphoma Society
Layout table for investigator information
Principal Investigator: Irene Ghobrial, MD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Irene Ghobrial, MD, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT02279394    
Other Study ID Numbers: 14-338
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021
Keywords provided by Irene Ghobrial, MD, Dana-Farber Cancer Institute:
Smoldering myeloma
Smoldering Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Smoldering Multiple Myeloma
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal